Bilthoven Biologicals (BBio) is a Netherlands-based end-to-end vaccine manufacturer of viral and bacterial vaccines, with its facilities in Bilthoven – Utrecht Science Park Bilthoven. A carve-out of the former Netherlands Vaccine Institute, it was acquired by Serum Institute of India (SII) in 2012.

Together with SII, BBio offers its unmatched end-to-end vaccine capabilities, making affordable vaccines and therapies available worldwide.

Since early 2025 with the European Commission registration of SIILTIBCY®, BBio also offers a diagnostic aid for detection of Mycobacterium tuberculosis infection, including disease, in adults and children aged 28 days or older. Intended for diagnostic use only by healthcare professionals, SIILTIBCY® is presented as a solution for intradermal injection containing Mycobacterium tuberculosis-derived antigens (rdESAT-6 and rCFP-10).